AbC-19 rapid antibody test

Last updated

The AbC-19 rapid antibody test is an immunological test for COVID-19 exposure developed by the UK Rapid Test Consortium and manufactured by Abingdon Health. It uses a lateral flow test to determine whether a person has IgG antibodies to the SARS-CoV-2 virus that causes COVID-19. The test uses a single drop of blood obtained from a finger prick and yields results in 20 minutes. The sensitivity of this test is 98.03% while the specificity is 99.56%. [1] This test is paired with an easy-to-use mobile app which allows a trained professional to generate an antibody test certificate for storing on a person's smartphone. [1]

Contents

See also

Related Research Articles

Antibody Immune system protein

An antibody (Ab), also known as an immunoglobulin (Ig), is a large, Y-shaped protein used by the immune system to identify and neutralize foreign objects such as pathogenic bacteria and viruses. The antibody recognizes a unique molecule of the pathogen, called an antigen. Each tip of the "Y" of an antibody contains a paratope that is specific for one particular epitope on an antigen, allowing these two structures to bind together with precision. Using this binding mechanism, an antibody can tag a microbe or an infected cell for attack by other parts of the immune system, or can neutralize it directly.

Blood type Classification of blood

A blood type is a classification of blood, based on the presence and absence of antibodies and inherited antigenic substances on the surface of red blood cells (RBCs). These antigens may be proteins, carbohydrates, glycoproteins, or glycolipids, depending on the blood group system. Some of these antigens are also present on the surface of other types of cells of various tissues. Several of these red blood cell surface antigens can stem from one allele and collectively form a blood group system.

Seroconversion Development of specific antibodies in the blood serum as a result of infection or immunization

In immunology, seroconversion is the development of specific antibodies in the blood serum as a result of infection or immunization, including vaccination. During infection or immunization, antigens enter the blood, and the immune system begins to produce antibodies in response. Before seroconversion, the antigen itself may or may not be detectable, but the antibody is absent. During seroconversion, the antibody is present but not yet detectable. After seroconversion, the antibody is detectable by standard techniques and remains detectable unless the individual seroreverts. Seroreversion, or loss of antibody detectability, can occur due to weakening of the immune system or waning antibody concentration over time. Seroconversion refers the production of specific antibodies against specific antigens, meaning that a single infection could cause multiple waves of seroconversion against different antigens. Similarly, a single antigen could cause multiple waves of seroconversion with different classes of antibodies. For example, most antigens prompt seroconversion for the IgM class of antibodies first, and subsequently the IgG class.

Serology is the scientific study of serum and other body fluids. In practice, the term usually refers to the diagnostic identification of antibodies in the serum. Such antibodies are typically formed in response to an infection, against other foreign proteins, or to one's own proteins. In either case, the procedure is simple.

In ABO hemolytic disease of the newborn maternal IgG antibodies with specificity for the ABO blood group system pass through the placenta to the fetal circulation where they can cause hemolysis of fetal red blood cells which can lead to fetal anemia and HDN. In contrast to Rh disease, about half of the cases of ABO HDN occur in a firstborn baby and ABO HDN does not become more severe after further pregnancies.

In the diagnostic laboratory virus infections can be confirmed by a multitude of methods. Diagnostic virology has changed rapidly due to the advent of molecular techniques and increased clinical sensitivity of serological assays.

InBios International, Inc. is a medical diagnostic company based in Seattle that specializes in the design, development, and manufacture of immunodiagnostic devices for infectious diseases. The company was founded in 1996 and, since its inception, has developed several technologies useful in designing rapid and ELISA based immunodiagnostic assays. InBios offers a number of life science reagents, along with a portfolio of more than 25 diagnostic products, including FDA Emergency Use Authorization for COVID-19 products and FDA-cleared ELISA kits for Zika, dengue, and West Nile and rapid test kits for Chagas and leishmaniasis. InBios is GMP compliant, FDA registered, USDA licensed and ISO 13485:2016 certified.

DiaSorin Italian biotechnoloty company

DiaSorin is an Italian multinational biotechnology company that produces and markets in vitro diagnostics reagent kits used in immunodiagnostics and molecular diagnostics and since July 2021, it is also active in the Life Science business. The group was founded in 2000 and is headquartered in Saluggia, Italy. Its production is at several plants located in Europe and the United States: Saluggia and Gerenzano (Italy), Dietzenbach (Germany), Stillwater, Minnesota (US), Dartford (UK). Following the acquisition of Luminex, the Company acquired five additional production plants located in the USA and in Canada (Toronto). The company is a constituent of the FTSE MIB index.

Rapid antigen test Fast medical lateral flow test

A rapid antigen test (RAT), sometimes called a rapid antigen detection test (RADT), antigen rapid test (ART), or often even just a rapid test, is a rapid diagnostic test suitable for point-of-care testing that directly detects the presence or absence of an antigen. It is commonly used for the detection of SARS-CoV-2, the virus that causes COVID-19. Rapid tests are a type of lateral flow tests that detect antigens, distinguishing it from other medical tests that detect antibodies or nucleic acid, of either laboratory or point-of-care types. Rapid tests generally give a result in 5 to 30 minutes, require minimal training or infrastructure, and have significant cost advantages.

Blood compatibility testing Testing to identify incompatibilities between blood types

Blood compatibility testing is conducted in a medical laboratory to identify potential incompatibilities between blood types in blood transfusion. It is also used to diagnose and prevent some complications of pregnancy that can occur when the baby has a different blood group from the mother. Blood compatibility testing includes blood typing, which detects the antigens on red blood cells that determine a person's blood type; testing for unexpected antibodies against blood group antigens ; and, in the case of blood transfusions, mixing the recipient's plasma with the donor's red blood cells to detect incompatibilities (crossmatching). Routine blood typing involves determining the ABO and RhD type, and involves both identification of ABO antigens on red blood cells and identification of ABO antibodies in the plasma. Other blood group antigens may be tested for in specific clinical situations.

COVID-19 testing Diagnostic testing for SARS-CoV-2 virus infection

COVID-19 testing involves analyzing samples to assess the current or past presence of SARS-CoV-2. The two main branches detect either the presence of the virus or of antibodies produced in response to infection. Molecular tests for viral presence through its molecular components are used to diagnose individual cases and to allow public health authorities to trace and contain outbreaks. Antibody tests instead show whether someone once had the disease. They are less useful for diagnosing current infections because antibodies may not develop for weeks after infection. It is used to assess disease prevalence, which aids the estimation of the infection fatality rate.

Immunity passport Medical record for travel purposes

An immunity passport, immunity certificate, health pass or release certificate is a document, whether in paper or digital format, attesting that its bearer has a degree of immunity to a contagious disease. Public certification is an action that governments can take to mitigate an epidemic.

Abingdon Health is a British manufacturer of lateral flow assay diagnostic tests, sometimes called rapid tests, lateral flow immunoassays (LFIA), lateral flow tests (LFT) or quick tests. Since its formation in 2008, Abingdon Health has grown to become an organisation of over 200 people and has developed and manufactured lateral flow rapid tests across multiple industries.

The UK Rapid Test Consortium (UK-RTC) is a United Kingdom industry consortium created to produce a lateral flow rapid test for COVID-19. Rapid tests are a form of COVID-19 testing technology that was originally developed from significant investment by the United Kingdom government to develop new forms of COVID-19 testing that provided advantages over existing forms such as PCR. Its members include Abingdon Health, BBI Solutions, CIGA Healthcare, Omega Diagnostics, and Oxford University.

Bamlanivimab is a monoclonal antibody developed by AbCellera Biologics and Eli Lilly as a treatment for COVID-19. The drug was granted an emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in November 2020, and 950,000 doses have been bought by the US government as of December 2020. In April 2021, the EUA was revoked.

CIGA Healthcare is a British manufacturer of lateral flow assay diagnostic tests. It is under contract to the British government for the supply of AbC-19 rapid antibody tests, a test for the presence of IgG antibody against the SARS-CoV-2 spike protein, as part of the UK Rapid Test Consortium program.

EpiVacCorona EpiVacCorona vaccine against COVID-19

EpiVacCorona is a peptide-based vaccine against COVID-19 developed by the VECTOR center of Virology. It consists of three chemically synthesized peptides that are conjugated to a large carrier protein. This protein is a fusion product of a viral nucleocapsid protein and a bacterial MBP protein. The third phase of a clinical trial, which should show whether the vaccine is able to protect people from COVID-19 or not, was launched in November 2020 with more than three thousand participants.

Development of COVID-19 tests

The development of COVID-19 tests was a major public health priority during the early months of the COVID-19 pandemic.

Nanocovax Vaccine candidate against COVID-19

Nanocovax is a Vietnamese COVID-19 vaccine candidate developed by Nanogen Pharmaceutical Biotechnology JSC. It is a subunit vaccine.

COVID-19 rapid antigen test Diagnosis test for a SARS-COV-2 infection

COVID-19 rapid antigen tests, also frequently called COVID-19 lateral flow tests, are rapid antigen tests used to detect SARS-COV-2 infection (COVID-19). They are quick to implement with minimal training, offered significant cost advantages, costing a fraction of other forms of COVID-19 testing and give users a result within 5–30 minutes. Rapid antigen tests are used in several countries as part of mass testing or population-wide screening approaches. They are thought to be valuable for identifying individuals who are asymptomatic and could potentially spread the virus to other people, who would otherwise not know they were infected. This differs from other forms of COVID-19 testing, such as PCR, that are generally seen to be a useful test for symptomatic individuals, as they have a higher sensitivity and can more accurately identify cases.

References

  1. 1 2 "AbC-19™ | COVID-19 Rapid Antibody Test and Certificate Solution | IgG". Abingdon Health plc. Retrieved 2021-08-02.